Skip to content

Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic

Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04387292
Acronym
SOCOVID
Enrollment
34
Registered
2020-05-13
Start date
2020-09-07
Completion date
2021-05-15
Last updated
2026-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19, Ophthalmopathy

Keywords

COVID19

Brief summary

Ophthalmologic damages secondary to COVID-19 coronavirus infection are little described. The ocular involvement is probably multiple, ranging from pathologies of the anterior segment such as conjunctivitis and anterior uveitis to disorders that threaten vision such as retinitis or optic neuropathy. On the other hand, in addition to this impairment, when patients are hospitalized for acute respiratory failure, complications related to possible resuscitation, medication prescriptions, positioning and oxygenation. COVID-19 itself, has several components: * An apoptotic action of the viral attack which will generate cellular destruction, whether pulmonary, cardiac or renal or maybe ocular * A secondary autoimmune action with the development of major vascular inflammation, possibly reaching the retinal, choroidal, and optic nerve vessels. A secondary hyper inflammatory syndrome with flashing hypercytokinemia and multi-organ decompensation is described in 3,7% to 4 ,3% of severe cases. * A thromboembolic action

Detailed description

Upon discharge from hospital for COVID-19 infection (or during a telephone call for patients already discharged at the start of the study), patients will be informed of the study. An ophthalmology appointment will be given to them between 4 and 6 months after their discharge. During the ophthalmology appointment, the patient's clinical data will be collected during an interview (medical and treatment history, blood group). The patient will benefit from a full ophthalmological examination.

Interventions

* Visual acuity (ETDRS exam) * Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test * Lipiview * Eye pressure measurement (air tonometer) * Wide field retinophotography * Multicolor and auto-fluorescence retinophotography * Indocyanine green retinal angiography * Optical coherence tomography (OCT) B posterior pole scan * OCT Angiography (OCT-A) of the optic nerve and posterior pole * Adaptive optics * Visual field (Humphrey)

Sponsors

Fondation Ophtalmologique Adolphe de Rothschild
Lead SponsorNETWORK

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients having been hospitalized for a confirmed COVID-19 infection (CT-scanner or PCR- Polymerase chain reaction)

Exclusion criteria

* Pregnant or breastfeeding woman

Design outcomes

Primary

MeasureTime frameDescription
Description of the ophthalmological problems observed6 months after discharge of hospitalizationMultimodal ophthalmologic imaging

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026